- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02132832
Buspirone, Stress, and Attentional Bias to Marijuana Cues
This project has two primary goals. The first goal is to further scientific understanding about marijuana abuse by examining two recognized factors in marijuana use and relapse: (1) stress/anxiety and (2) atypical reactivity to marijuana-related stimuli (e.g., attentional bias). The second goal is to attenuate the influence of stress/anxiety and attentional bias to marijuana stimuli via administration of buspirone.
Buspirone is uniquely suited to this project because it has effects on neurotransmitter systems known to modulate both stress/anxiety and attentional bias.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
For nearly 40 years marijuana has remained the most widely used illicit drug in the US, with more than 50% of first-time users < age 18. Marijuana accounts for ≈ 60% of illicit substance use disorders (SUD) in the US, bearing by percent the largest US public health burden among illicit substances. Across preclinical, human laboratory, and clinical interview data, there is compelling evidence that the phenomenon of cue reactivity is related to drug seeking and relapse. Attentional bias is a measurable component of cue reactivity, and can be operationally defined as differential attention (e.g., reaction time difference) towards drug-related stimuli vs. neutral stimuli. This phenomenon has been demonstrated in SUD populations across many classes of abused drugs, including alcohol, nicotine, stimulants, opiates, and - importantly - marijuana. Cue reactivity and attentional bias are exacerbated by acute and chronic stress and anxiety. Notably, stress is a well-documented predictor of marijuana abuse and marijuana relapse. Therapeutic interventions that attenuate attentional bias to marijuana cues are a potentially important component in the treatment of marijuana SUD. Due to the well-documented association with stress, an intervention that simultaneously addresses both stress and attentional bias could be uniquely efficacious. Currently, few pharmacotherapies exist for marijuana SUD, and none are presently known to address attentional bias to marijuana cues. This application will explore the potential of the anxiolytic buspirone to modify attentional bias and stress. Buspirone is a unique compound marked by modulation of both serotonin (5-HT1A) and dopamine D3 receptors. Importantly, the 5-HT1A receptor is known to play a key role in stress related anxiety, and preclinical work indicates that D3 antagonists significantly decrease cue reactivity to a number of abused drugs. This combination of effects suggests buspirone may be advantageous in targeting both stress and attentional bias as factors that contribute to problem marijuana use.
Accordingly, this project seeks to examine the effects of chronic buspirone administration on attentional bias and stress/anxiety in marijuana SUD. Using laboratory-based methodologies sensitive to attentional bias towards marijuana cues and well validated measures of stress and anxiety, we will examine if buspirone's unique mechanism of action will (a) produce an attenuation of attentional bias to marijuana cues, and (b) be most pronounced under conditions in which attentional bias is related to high levels of stress and anxiety.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- University of Texas Health Science Center - Houston
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Marijuana substance use disorder based on a score of ≥ 13 on the Cannabis Use Disorders Identification Test - Revised (CUDIT-R)
- a score of ≥ 4 on the Cannabis Abuse Screening Test (CAST)
- meeting criteria for a marijuana substance use disorder based on the Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders IV (DSM-IV)
Exclusion Criteria:
- Current DSM-IV Axis I disorder other than marijuana use disorder
- serious medical illness requiring ongoing medical treatment, which could affect the central nervous system, or any other medical contraindication (e.g., renal, cardiovascular, pulmonary, blood) as determined by medical screening
- a positive pregnancy test or breast feeding (females)
- concomitant use of prescription medications that could affect the central nervous system
- active suicidal ideation or Beck Depression Inventory II score greater than 19
- positive urine drug screen for drugs other than marijuana or positive breath alcohol screen
- Shipley-2 test of cognitive aptitude score outside 2 SD units of the published composite score average
- smoking > 10 nicotine cigarettes per day / Fagerstrom Score > 4
- taking meds known to have significant drug interactions with buspirone.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Buspirone
Buspirone is administered orally twice per day (9:00 AM and 6:00 PM) for 3 weeks.
10 mg buspirone is administered on days 1-4, then the dose is increased by 10 mg every 3 days to a maximum of 40 mg buspirone on days 10-19.
|
Buspirone is an anxiolytic compound marked by modulation of both 5-HT1A and D3 receptors.
Buspirone is administered orally twice per day (9:00 AM and 6:00 PM) for 3 weeks.
10 mg buspirone is administered on days 1-4, then the dose is increased by 10 mg every 3 days to a maximum of 40 mg buspirone on days 10-19.
|
Placebo Comparator: Placebo
Placebo is administered orally twice per day (9:00 AM and 6:00 PM) for 3 weeks.
|
Placebo is administered orally twice per day (9:00 AM and 6:00 PM) for 3 weeks.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Attentional Bias to Marijuana Specific Stimuli Measured Via Analysis of Eye Movements
Time Frame: week 1
|
Eye movements are analyzed using a MiraMetrix S2 Eyetracker.
This outcome measure reports a ratio: [(number of anti-saccade errors with marijuana-related images) divided by (total number of anti-saccade errors with marijuana-related images or neutral images)].
Anti-saccade errors are when the subject fails to inhibit fixation onto the image.
|
week 1
|
Attentional Bias to Marijuana Specific Stimuli Measured Via Analysis of Eye Movements
Time Frame: week 2
|
Eye movements are analyzed using a MiraMetrix S2 Eyetracker.
This outcome measure reports a ratio: [(number of anti-saccade errors with marijuana-related images) divided by (total number of anti-saccade errors with marijuana-related images or neutral images)].
Anti-saccade errors are when the subject fails to inhibit fixation onto the image.
|
week 2
|
Attentional Bias to Marijuana Specific Stimuli Measured Via Analysis of Eye Movements
Time Frame: week 3
|
Eye movements are analyzed using a MiraMetrix S2 Eyetracker.
This outcome measure reports a ratio: [(number of anti-saccade errors with marijuana-related images) divided by (total number of anti-saccade errors with marijuana-related images or neutral images)].
Anti-saccade errors are when the subject fails to inhibit fixation onto the image.
|
week 3
|
Stress as Assessed by the Perceived Stress Scale
Time Frame: week 1
|
The Perceived Stress Scale is a 10 item scale that was developed to measure the degree to which individuals appraise their life as stressful and has been widely used in health studies.
The scale has a 5-point Likert response format.
The total score is calculated by summing responses.
The questions are general in nature and relatively content free with regard to specific population groups.
The range of scores is 0-40, with 40 indicating the most stress.
|
week 1
|
Stress as Assessed by the Perceived Stress Scale
Time Frame: week 2
|
The Perceived Stress Scale is a 10 item scale that was developed to measure the degree to which individuals appraise their life as stressful and has been widely used in health studies.
The scale has a 5-point Likert response format.
The total score is calculated by summing responses.
The questions are general in nature and relatively content free with regard to specific population groups.
The range of scores is 0-40, with 40 indicating the most stress.
|
week 2
|
Stress as Assessed by the Perceived Stress Scale
Time Frame: week 3
|
The Perceived Stress Scale is a 10 item scale that was developed to measure the degree to which individuals appraise their life as stressful and has been widely used in health studies.
The scale has a 5-point Likert response format.
The total score is calculated by summing responses.
The questions are general in nature and relatively content free with regard to specific population groups.
The range of scores is 0-40, with 40 indicating the most stress.
|
week 3
|
Anxiety as Assessed by the Zung Self-Rated Anxiety Scale
Time Frame: week 1
|
The Zung Self-Rated Anxiety Scale is a widely-used 20 item scale that is scored on a Likert-type scale of 1-4, with 15 questions concerning increasing anxiety levels and five questions concerning decreasing anxiety levels. The scale focuses on the most common general anxiety symptoms and means of coping with stressors that produce anxiety. The range of scores is 20-80:
|
week 1
|
Anxiety as Assessed by the Zung Self-Rated Anxiety Scale
Time Frame: week 2
|
The Zung Self-Rated Anxiety Scale is a widely-used 20 item scale that is scored on a Likert-type scale of 1-4, with 15 questions concerning increasing anxiety levels and five questions concerning decreasing anxiety levels. The scale focuses on the most common general anxiety symptoms and means of coping with stressors that produce anxiety. The range of scores is 20-80:
|
week 2
|
Anxiety as Assessed by the Zung Self-Rated Anxiety Scale
Time Frame: week 3
|
The Zung Self-Rated Anxiety Scale is a widely-used 20 item scale that is scored on a Likert-type scale of 1-4, with 15 questions concerning increasing anxiety levels and five questions concerning decreasing anxiety levels. The scale focuses on the most common general anxiety symptoms and means of coping with stressors that produce anxiety. The range of scores is 20-80:
|
week 3
|
Stress as Assessed by the Visual Analogue Stress Scale-Current (VASS-C)
Time Frame: week 1
|
With the Visual Analogue Stress Scale - Current (VASS-C), current stress level is ranked on a 0 - 10 visual analog scale, with 0 as no stress and 10 as extreme stress, cued by the question "Please rate your current stress level."
|
week 1
|
Stress as Assessed by the Visual Analogue Stress Scale-Current (VASS-C)
Time Frame: week 2
|
With the Visual Analogue Stress Scale - Current (VASS-C), current stress level is ranked on a 0 - 10 visual analog scale, with 0 as no stress and 10 as extreme stress, cued by the question "Please rate your current stress level."
|
week 2
|
Stress as Assessed by the Visual Analogue Stress Scale-Current (VASS-C)
Time Frame: week 3
|
With the Visual Analogue Stress Scale - Current (VASS-C), current stress level is ranked on a 0 - 10 visual analog scale, with 0 as no stress and 10 as extreme stress, cued by the question "Please rate your current stress level."
|
week 3
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Scott D. Lane, PhD, The University of Texas Health Science Center, Houston
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Chemically-Induced Disorders
- Substance-Related Disorders
- Marijuana Abuse
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Tranquilizing Agents
- Psychotropic Drugs
- Serotonin Agents
- Serotonin Receptor Agonists
- Anti-Anxiety Agents
- Buspirone
Other Study ID Numbers
- buspirone, stress, marijuana
- R21DA034825 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cannabis Use Disorder
-
The University of Tennessee, KnoxvilleColorado State UniversityActive, not recruitingCannabis Use Disorder, Mild | Cannabis Use Disorder, Moderate | Cannabis Use Disorder, SevereUnited States
-
Medical University of South CarolinaNational Institute on Drug Abuse (NIDA)RecruitingCannabis Use Disorder, Mild | Cannabis Use Disorder, Moderate | Cannabis Use Disorder, SevereUnited States
-
Medical University of South CarolinaNational Institute on Drug Abuse (NIDA)RecruitingBipolar Disorder | Cannabis Use | Bipolar I Disorder | Cannabis Use Disorder, Mild | Cannabis Use Disorder, Moderate | Cannabis Use Disorder, Severe | Bipolar II Disorder | Schizoaffective Disorder, Bipolar TypeUnited States
-
Monash UniversityTurning PointCompletedCannabis Use Disorder, Moderate | Cannabis Use Disorder, SevereAustralia
-
Oregon Research InstituteCompletedCannabis Use Disorder, Mild | Cannabis Use Disorder, ModerateUnited States
-
McMaster UniversityCenter for Medicinal Cannabis ResearchNot yet recruitingCannabis Use Disorder, Moderate | Cannabis Use Disorder, Severe
-
Ellen HerbstTobacco Related Disease Research ProgramRecruitingTobacco Use Disorder | Cannabis Use | Drug Use DisorderUnited States
-
VA Office of Research and DevelopmentRecruitingTobacco Use Disorder | Cannabis Use DisorderUnited States
-
Elias DakwarRecruitingAddiction | Cannabis Dependence | Cannabis Use | Substance Abuse | Cannabis Abuse | Cannabis Use DisorderUnited States
-
Dartmouth-Hitchcock Medical CenterNational Institute on Drug Abuse (NIDA)Completed
Clinical Trials on Buspirone
-
Johns Hopkins Bloomberg School of Public HealthJohns Hopkins University; Massachusetts General Hospital; National Institute... and other collaboratorsCompleted
-
Massachusetts General HospitalBrainCells Inc.CompletedMajor Depressive DisorderUnited States
-
Beijing Union Pharmaceutical Factory LtdR&G Pharma Studies Co.,Ltd.RecruitingGeneralized Anxiety DisorderChina
-
Spaulding Rehabilitation HospitalRecruitingSpinal Cord InjuriesUnited States
-
Par Pharmaceutical, Inc.Phoenix International Life Sciences, Inc.CompletedTo Determine Bioequivalence Under Fed ConditionsCanada
-
Par Pharmaceutical, Inc.Phoenix International Life Sciences, Inc.CompletedTo Determine Bioequivalence Under Fasting ConditionsCanada
-
Laikο General Hospital, AthensCompleted
-
University of OxfordCompleted
-
Nordic Life Science Pipeline Inc.United States Department of DefenseCompleted
-
Northwestern UniversityNational Alliance for Research on Schizophrenia and DepressionCompletedSchizophrenia | Schizoaffective DisorderUnited States